Last reviewed · How we verify
Naphcon Forte (NAPHAZOLINE)
Naphcon Forte (Naphazoline) is a small molecule drug developed by Novartis that targets the alpha-2A adrenergic receptor. It is classified as a naphazoline and was FDA approved in 1971 for the treatment of ocular itching and red eye. As an off-patent medication, Naphcon Forte is available from multiple generic manufacturers. Key safety considerations include potential rebound effects and interactions with other medications. Naphcon Forte is a commercially available medication with a long history of use.
At a glance
| Generic name | NAPHAZOLINE |
|---|---|
| Sponsor | Novartis |
| Drug class | Non-Standardized Chemical Allergen [EPC] |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Ocular Itching
- Red eye
Common side effects
Key clinical trials
- QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT) (NA)
- Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors (PHASE1)
- Safety and Tolerability of PRO-185 (PHASE1)
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. (PHASE3)
- Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease (NA)
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. (PHASE3)
- Efficacy and Safety of Pediatric Drugs in Nasal Congestion (PHASE3)
- Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naphcon Forte CI brief — competitive landscape report
- Naphcon Forte updates RSS · CI watch RSS
- Novartis portfolio CI